ReWalk Robotics Reports Third Quarter 2017 Financial Results -- 24% YOY growth in Q3 revenue to $1.7 million - -- Coverage allowed by DGUV and Barmer in Germany of ReWalk personal devices -- YOKNEAM

Robotics Reports Third Quarter 2017 Financial Results

-- 24% YOY growth in Q3 revenue to $1.7 million -

-- Coverage allowed by DGUV and Barmer

in Germany of ReWalk personal devices --

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 2, 2017

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial

results for the three- and nine-month periods ended September 30, 2017.

Highlights of and subsequent to the third quarter include:

"Our business continues to deliver

year over year growth as we focus on advancing our key initiatives including insurance reimbursement coverage for the ReWalk Personal

device and progressing our innovative soft suit exoskeleton technology, the Restore, designed for individuals who experienced a

stroke. We view the Restore system as a platform technology which we believe has significant applications beyond stroke in potentially

treating multiple sclerosis, Parkinson's disease, and other lower limb disabilities," stated

Larry Jasinski, Chief Executive Officer.

"We have begun pre-clinical testing

of the Restore system to study its safety and use in the rehabilitation setting for the mobility needs of stroke patients. We are

targeting a clinical trial with the Restore system to begin in early 2018 and aim to commercialize the system for use by stroke

patients in Europe in late 2018, followed by the United States in late 2018 or early 2019, subject to the timing and receipt of

CE mark and Food and Drug Administration clearance," he added.

Third Quarter 2017 Financial

Total revenue was $1.7 million for

the third quarter of 2017, an increase of 24% compared with $1.4 million in the third quarter of 2016. 16 ReWalk units were placed

during the third quarter, compared with 23 ReWalk systems placed in the prior year period, of which 10 were placed in the U.S.,

three in Europe, and three with distributors. An additional 8 rental units from previous periods converted to purchases. For the

first three quarters of 2017, a total of 19 rental units converted to sales.

Gross margin improved to 41% during

the third quarter of 2017 compared to 21% in the prior year period, primarily attributable to sales mix, an increase in the conversion

of rental units to purchases, and lower product costs.

ReWalk Robotics Reports Third Quarter 2017 Financial Results

Total operating expenses in the third

quarter of 2017 were $6.1 million compared with $7.7 million in the third quarter of 2016. Operating

expenses in the third quarter of 2017 reflect initiatives to reduce spending announced earlier in 2017.

Net loss was $5.8 million for the third

quarter of 2017 compared with a net loss of $7.9 million in the prior year quarter. Non-GAAP net loss for the third quarter was

$4.8 million compared with a non-GAAP net loss of $6.7 million in the third quarter of 2016.*

*A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

ReWalk ended the third quarter of 2017

with $12.9 million in cash and cash equivalents.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 4999768.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic

exoskeletons for individuals with spinal cord injury. ReWalk's

mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development

of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information

on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

ReWalk Robotics Reports Third Quarter 2017 Financial Results

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities

Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and,

in some cases, may be identified by words like "anticipate," "assume," "believe," "continue,"

"could," "estimate," "expect," "intend," "may," "plan,"

"potential," "predict," "project," "future," "will," "should,"

"would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release

are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that

are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's

actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's

expectations regarding future growth, including its ability to increase sales in its existing geographic markets, expand to new

markets and achieve its planned expense reductions; the conclusion of ReWalk's management for the financial statements for

the third quarter of 2017 and for fiscal 2016, and the opinion of ReWalk's auditors in their report on the Company's

financial statements for fiscal 2016, that there are substantial doubts as to ReWalk's ability to continue as a going concern;

ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to

achieve reimbursement from third-party payors for its products; ReWalk's expectations as to its clinical research program

and clinical results; ReWalk's expectations as to the results of, and the Food and Drug Administration's potential

regulatory developments with respect to, ReWalk's mandatory post-market 522 surveillance study; the outcome of ongoing shareholder

class action litigation relating to ReWalk's initial public offering; ReWalk's ability to repay its secured indebtedness;

ReWalk's ability to improve its products and develop new products; ReWalk's ability to maintain adequate protection

of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk's ability to gain

and maintain regulatory approvals; ReWalk's ability to secure capital from its equity and debt financings in light of limitations

under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings

may dilute ReWalk's shareholders or restrict its business; ReWalk's ability to use effectively the proceeds of offerings

of securities; ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers;

the impact of the market price of ReWalk's ordinary shares on the determination of whether ReWalk is a passive foreign investment

company; ReWalk's ability to comply with the continued listing requirements of the NASDAQ Capital Market and the risk that

its ordinary shares will be delisted if it cannot do so; ReWalk's compliance with medical device reporting regulations to

report adverse events involving its products and the potential impact of such adverse events on ReWalk's ability to market

and sell its products; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report

on Form 10-K for the year ended December 31, 2016, as amended, filed with the U.S. Securities and Exchange Commission and other

documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made

in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ

from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except

as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new

information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted

Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP net loss is helpful to its investors. This measure is not

prepared in accordance with GAAP.

For the three- and nine-months ended September 30, 2017 and

2016, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation

and (iii) non-cash financial expenses.

ReWalk Robotics Reports Third Quarter 2017 Financial Results

Because of varying available valuation methodologies, subjective

assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, ReWalk believes that providing